Cardiologists Accidentally Built A Cancer-Starving Protocol - The Cholesterol Drug That Does Three Things Statins Can’t
The cardiovascular injection that outperformed statins in cancer survival
Nothing in this article constitutes medical advice. The science discussed is published, peer-reviewed research. Its application to any individual’s treatment decisions requires a qualified clinician who can assess their specific circumstances.
A major cardiology trial showed that adding a PCSK9 inhibitor to statin therapy could drive measurable regression of coronary plaque in patients with coronary artery disease. But the deeper implication may reach beyond cardiology, because the same cholesterol-handling machinery targeted in plaque biology is also central to the metabolic survival and immune evasion of many cancers.
The cardiovascular result that changed the frame
The GLAGOV trial tested evolocumab, a PCSK9 inhibitor, on top of statin therapy in patients with coronary disease and found greater atheroma regression than statins alone. LDL cholesterol fell to about 36.6 mg/dL in the evolocumab group compared with about 93 mg/dL in the statin-only group. Plaque regression occurred in 64.3% of patients receiving evolocumab plus statin versus 47.3% in those on statin alone.
This was presented as a plaque story, but it can also be read as a proof-of-principle that the cholesterol pathway can be pushed much harder in humans than conventional statin therapy alone would suggest. Once that is recognized, the oncology implications become much harder to ignore.
The Problem with the Single-Agent Mindset
Before I tell you more about evolocumab, I want to tell you about the mistake I see most often in integrative oncology.
